GlycoEra
GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic
First-in-human trial to evaluate the potential for rapid, deep and selective IgG4 removal Healthy subject data expected in the first half of 2027 to…
